File Download
Supplementary

Conference Paper: Phase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm

TitlePhase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm
Authors
PublisherInternational Liver Cancer Association.
Citation
Phase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm. In Final program & book of abstracts: the 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013, p. 16 How to Cite?
DescriptionThe 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013
Oral Communications, Saturday 14 September, 2013, 0-021
Persistent Identifierhttp://hdl.handle.net/10722/195839

 

DC FieldValueLanguage
dc.contributor.authorTak, WY-
dc.contributor.authorLin, SM-
dc.contributor.authorWang, Y-
dc.contributor.authorZheng, J-
dc.contributor.authorIzzo, F-
dc.contributor.authorPark, SY-
dc.contributor.authorChen, MH-
dc.contributor.authorWong, SN-
dc.contributor.authorXu, R-
dc.contributor.authorPeng, CY-
dc.contributor.authorChiou, YY-
dc.contributor.authorHuang, GT-
dc.contributor.authorLee, JY-
dc.contributor.authorSherman, M-
dc.contributor.authorAbdullah, BJJ-
dc.contributor.authorLee, JS-
dc.contributor.authorWang, JH-
dc.contributor.authorBorys, N-
dc.contributor.authorPoon, RTP-
dc.contributor.authorLencioni, R-
dc.date.accessioned2014-03-14T02:39:11Z-
dc.date.available2014-03-14T02:39:11Z-
dc.identifier.citationPhase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm. In Final program & book of abstracts: the 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013, p. 16-
dc.identifier.urihttp://hdl.handle.net/10722/195839-
dc.descriptionThe 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013-
dc.descriptionOral Communications, Saturday 14 September, 2013, 0-021-
dc.languageeng-
dc.publisherInternational Liver Cancer Association.-
dc.relation.ispartofFinal program & book of abstracts-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titlePhase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cmen_US
dc.typeConference_Paperen_US
dc.identifier.emailPoon, RTP: poontp@hku.hk-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros700001468-
dc.identifier.spage16-
dc.identifier.epage16-
dc.publisher.placeUnited States-
dc.customcontrol.immutableyiu 140314-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats